EULAR2024| 三生国健SSGJ-613(IL-1β)急性痛风性关节炎II期数据

文章预览

SSGJ-613 RELIEVES PAIN AND REDUCES THE RISK OF ACUTE FLARES IN PATIENTS WITH GOUT: RESULTS OF A RANDOMIZED, DOUBLE-BLIND, PHASE II STUDY Background:   Gouty arthritis is a common inflammatory arthritis caused by the deposition of monosodium urate (MSU) crystals in joints with the prevalence of 1% to 3% in China. Interleukin 1-β (IL-1β) is a key mediator of acute gouty flares, and anti-IL-1β therapy has been proven to be an important option for the treatment of gouty arthritis. However, no IL-1β inhibitors are available in China. Therefore, the effectiveness of IL-1β inhibitors in Chinese patients with gout remains unclear. Objectives:  This is a double-blind, double-dummy, active-controlled phase II study to assess the efficacy and safety of SSGJ-613, a fully human anti-interleukin 1β monoclonal antibody, in Chinese patients with gout. Methods:  Key inclusion criteria were: patients aged 18 to 65 years and meeting the ACR criteria of gout; presence of an acute Gouty Arthritis ………………………………